The studies reported in this book almost unanimously demonstrate that, in patients with symptomatic coronary atherosclerosis, lipid lowering retards progression of the disease process and may even lead to regression. As suggested by most angiographic trials, in particular by REGRESS1, this is accompanied by a favourable effect on morbidity and mortality. A beneficial clinical effect was also convincingly demonstrated by the 4S study2 which was designed to determine the clinical effects of lipid lowering in patients with coronary atherosclerosis and moderately elevated serum cholesterol levels (5.5–8.0mml/L).
KeywordsCoronary Atherosclerosis Lipid Lowering Coronary Flow Reserve Serum Lipid Level Scandinavian Simvastatin Survival Study
Unable to display preview. Download preview PDF.
- 1.Jukema JW, Bruschke AVG, Van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–40.PubMedGoogle Scholar
- 2.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
- 4.Grundey SM. National cholesterol education program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;89:1329–445.Google Scholar